Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





GENETWORx Labs Launches New Breakthrough Diagnostic Flu A-B/COVID-19/RSV Combination Test

By LabMedica International staff writers
Posted on 02 Dec 2020
TCA/GENETWORx Labs (Glen Allen, VA, USA) has unveiled a new breakthrough diagnostic Flu A-B/COVID-19/RSV combination test that provides patients with early detection of all three separate respiratory viruses with just one test sample.

With people inside homes, businesses, and schools during the cold weather months where there is less ventilation, the COVID-19 virus coupled with influenza and RSV (Respiratory Syncytial Virus) pose a formidable and unprecedented infectious disease threat, particularly since these viruses share similar symptoms. More...
To help battle this triple threat, the new TCA/GENETWORx Combo PCR test provides patients the ability to detect strands of influenza A and B, RSV, and COVID-19 all from a single sample. The molecular diagnostic PCR test detects two types of influenza viruses - influenza A and B - and differentiates them from RSV, and SARS-CoV-2, the virus that causes COVID-19. The Flu A-B/COVID Combo Test provided by GENETWORx has a 98% accuracy rate for influenza, 99% for COVID-19, and 96% for RSV.

The capability to test for influenza A/B, RSV, and COVID-19 from a single mid-turbinate or nasopharyngeal swab sample means less discomfort for patients when compared with collecting a separate sample for each test. Testing a single sample for several pathogens uses fewer resources and takes less time when compared with running several individual tests on multiple samples to detect different pathogens.

An approval date for a COVID-19 vaccine is still yet to be determined and the flu vaccine is dependent on which strain of influenza is circulating each year. There is currently no vaccine for RSV. Even with the correct strain, the flu vaccine is not 100% reliable. With all the unknowns and risks associated with this upcoming flu and RSV season, the new TCA/GENETWORx test is an important advancement in diagnostic medicine during the pandemic.

"With this new combination test, healthcare providers can provide an accurate diagnosis to patients and treat them with the appropriate measures. Patients then can observe appropriate quarantine measures to stop the spread," said William Miller, CEO of GENETWORx Labs. "Having a combination test that detects three different viruses is a healthcare breakthrough for both providers and patients and will save lives. The Combo test is also easier on patients since only one sample is needed for three answers."

Related Links:
TCA/GENETWORx Labs


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.